Microarray-based mRNA expression profiling of leukemia cells treated with the flavonoid, casticin

Area of Science:

• Phytochemistry
• Cancer Biology
• Molecular Pharmacology

Background:

• Natural polyphenols are recognized for their potential anti-tumor properties.
• Acute T-lymphoblastic leukemia (T-ALL) poses a significant therapeutic challenge, particularly with the emergence of multidrug resistance.
• Evaluating novel compounds for efficacy against resistant cancer cell lines is crucial for developing new treatments.

Purpose of the Study:

• To assess the anti-leukemic activity of 15 plant-derived polyphenols against a doxorubicin-sensitive and a multidrug-resistant T-ALL cell line.
• To identify the most potent polyphenol compound for further investigation.
• To explore the molecular mechanisms underlying the action of the most effective compound.

Main Methods:

• Cultured doxorubicin-sensitive (CCRF-CEM) and multidrug-resistant (CEM/ADR5000) T-ALL cell lines.
• Assessed the cytotoxic effects of 15 plant polyphenols using IC50 value determination.
• Conducted microarray-based mRNA expression profiling on casticin-treated CCRF-CEM cells.

Main Results:

• Casticin exhibited the highest potency, with low IC50 values in both sensitive (0.28 ± 0.02 μM) and resistant (0.44 ± 0.17 μM) T-ALL cells.
• Other tested polyphenols showed varying degrees of activity, with IC50 values ranging from 1.52 μM to 164.1 μM.
• Casticin treatment altered gene expression in CCRF-CEM cells, implicating pathways such as NF-κB, p38MAPK, and those involving histones and follicle-stimulating hormone.

Conclusions:

• Casticin is a highly potent natural polyphenol with significant anti-leukemic activity against both drug-sensitive and drug-resistant T-ALL.
• The anti-cancer effects of casticin are associated with the modulation of critical cellular signaling pathways.
• Casticin represents a promising candidate for further development as a therapeutic agent for T-ALL.